Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | CTSA | P10619 | 11/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL318486 | 0.83 | CTSA (0.47) | CTSAPDK2NPSR1ERN1 | |
| SCHEMBL11906490 | 0.81 | GABRA5 (0.41) | GABRA5CTSAXDHPDK2MLYCD | |
| SCHEMBL11907190 | 0.78 | PIM1 (0.45) | GABRA5XDHPDK2MLYCDALDH1A1 | |
| SCHEMBL1711474 | 0.75 | KMO (0.44) | CTSA | |
| SCHEMBL319370 | 0.75 | AR (0.37) | CTSAXDHALDH1A1 | |
| SCHEMBL1711956 | 0.75 | CTSA (0.50) | CTSAALDH1A1 | |
| SCHEMBL4436068 | 0.74 | PIM2 (0.52) | XDHPDK2MLYCDNPSR1ERN1 | |
| SCHEMBL11909195 | 0.73 | PIM1 (0.41) | GABRA5XDHPDK2MLYCDMAPK14 | |
| SCHEMBL13146304 | 0.73 | MLYCD (0.54) | PDK2MLYCDMEN1ALDH1A1KMT2A | |
| SCHEMBL31079673 | 0.73 | MLYCD (0.54) | PDK2MLYCDMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| EP-2590968-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | Novartis AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | PIM1, GSK3A, GSK3B | GABRA5 2187/4885CTSA 3138/4885XDH 2702/4885 |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | GABRA5 2164/4885CTSA 4190/4885XDH 2634/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | GABRA5 2164/4885CTSA 4190/4885XDH 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.